In a KRAS-driven mouse lung-tumor model, daily Torin2 monotherapy did not significantly inhibit tumor volume over four weeks. Combining Torin2 with the MEK inhibitor AZD6244 reduced tumor growth. Partial pathway recovery during prolonged monotherapy limits extrapolation from short-term target suppression. [1]
In an independent pancreatic-tumor mouse study, Torin 2 reduced tumor volume, and the Torin2–metformin combination also reduced tumor weight versus vehicle. High-dose Torin2 was reported toxic, with 3/10 animals surviving. Unequal attrition, including losses in controls, limits efficacy and tolerability comparisons. [2]
Single-agent and combination effects in KRAS-driven lung tumors
Animal study · Mice bearing genetically engineered KRAS G12D-driven lung tumors [1]
Over 4 weeks, neither Torin2 nor AZD6244 alone produced significant tumor-volume inhibition as reported by the authors, whereas their combination reduced tumor growth. Target suppression after short treatment partly recovered during prolonged monotherapy.
Conditions shared by the study groups
- Frequency
- Daily
- Treatment course
- 4 weeks
- Torin2 alone
- Model: Mice bearing genetically engineered KRAS G12D-driven lung tumors
- Vehicle: Torin2 suspended in saline
- Reported limits: MRI bar error definition is not stated in the caption; exact volumes are not inferred. Route wording in retained manuscript is corrupted (“garage daily”); route is not normalized.
- AZD6244 alone
- Model: Mice bearing genetically engineered KRAS G12D-driven lung tumors
- Vehicle: 0.5% methylcellulose and 0.4% polysorbate
- Reported limits: No longitudinal vehicle MRI series shown in Fig. 5B. Route wording in retained manuscript is corrupted (“garage daily”); route is not normalized.
- Torin2 + AZD6244
- Model: Mice bearing genetically engineered KRAS G12D-driven lung tumors
- Vehicle: Torin2: saline; AZD6244: 0.5% methylcellulose and 0.4% polysorbate
- Reported limits: Exact effect size and statistical comparator are not reconstructed from the plot. Route wording in retained manuscript is corrupted (“garage daily”); route is not normalized.
Methods and source locations
Compound reported in the paper: Torin 2; Compound label in the paper: Torin2
Evidence concerns the reported experimental Torin2 material; supplier or lot equivalence is not established.
Results: Anti-tumor efficacy of combined Torin2/AZD6244 treatment in a KRAS-driven model of lung cancer; Fig. 5A–E; treatment and MRI methods
Torin2 alone · Fig. 5A–D and caption; efficacy Results; Mice cohort and drug treatment; MRI and PET/CT study
AZD6244 alone · Fig. 5A–D and caption; efficacy Results; Mice cohort and drug treatment; MRI and PET/CT study
Torin2 + AZD6244 · Fig. 5A–D and caption; efficacy Results; Mice cohort and drug treatment; MRI and PET/CT study
Pancreatic-tumor response and high-dose tolerability
Animal study · C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors [2]
After 12 days, all active-treatment groups had lower tumor volume than DMSO control in Table 1. Only the Torin2–metformin combination had a statistically significant tumor-weight reduction versus control. High-dose Torin2 was reported toxic, with only 3/10 mice surviving; attrition also affected control and other groups.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Daily
- Treatment course
- 12 days
- Vehicle
- DMSO control; active-arm formulation not separately specified in the adopted text
- DMSO control
- Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
- Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
- Low-dose Torin2
- Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
- Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
- High-dose Torin2
- Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
- Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
- Metformin alone
- Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
- Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
- Torin2 + metformin
- Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
- Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
Methods and source locations
Compound reported in the paper: Torin 2; Compound label in the paper: Torin2
Evidence concerns the reported experimental Torin2 material; supplier or lot equivalence is not established.
Methods: Reagents and orthotopic animal treatment; Results: tumor response; Table 1; Fig. 1 and caption
Reported survival at study endpoint: Counts as labeled in Table 1; not a Kaplan–Meier analysis — Table 1 Survival row; tumor response Results
DMSO control · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results
Low-dose Torin2 · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results
High-dose Torin2 · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results
Metformin alone · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results
Torin2 + metformin · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results